COMMUNIQUÉS West-GlobeNewswire

Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019
06/05/2019
Press Release – No. 09 / 2019 Zealand Pharma hosts conference call on May 16 at 4 pm CET (10 am EST) to present first quarter results for 2019 Copenhagen, May 6, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR [...]
Share buy-back week 18/2019
06/05/2019
Announcement 6 May 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling up [...]
Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting
06/05/2019
Montrouge, France, May 3, 2019 Ordinary and Extraordinary General Meeting of May 24, 2019 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – [...]
Assemblée Générale Mixte du 24 mai 2019 - Modalités de mise à disposition des documents préparatoires à l’Assemblée
06/05/2019
Montrouge, France, le 3 mai (22h30 CEST) 2019 Assemblée Générale Mixte du 24 mai 2019 Modalités de mise à disposition des documents préparatoires à l’Assemblée DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – [...]
LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals
06/05/2019
Preliminary data from a voluntary open label extension (OLE) study indicates that the time to re-treatment with Liproca® Depot in prostate cancer patients is potentially longer than anticipated. This information comes [...]
Reminder: C-RAD Web Presentation Interim Report Q1 2019
06/05/2019
Presentation of the report for the first quarter of the fiscal year 2019: Date: Wednesday May 8, 2019 / kl. 13:00 Venue: Online Presentation Topic: C-RAD Interim Report Q1 2019 Procedure: Please register online through [...]
Herantis Pharma publishes newsletter for March-April
06/05/2019
Herantis Pharma publishes newsletter for March-April Herantis Pharma Plc Press release 6 May 2019 at 9:00 am Herantis Pharma plc (“Herantis”) has published its newsletter for March-April. The newsletter is also attached [...]
ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
06/05/2019
LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug [...]
ERYTECH propose la nomination du Dr. Jean-Paul Kress au poste de Président du Conseil d’administration
06/05/2019
LYON, France, 06 mai 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), société biopharmaceutique en phase clinique développant des thérapies innovantes par encapsulation de substances [...]
Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019
06/05/2019
Press Release Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019 Enrollment rate now at 90% Key Opinion Leader endorsement of the potential for NCX 470 in [...]
Nicox : Présentation sur l’étude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters à la conférence ASCRS 2019
06/05/2019
Communiqué de presse Nicox : Présentation sur l’étude clinique de phase 2 pour le NCX 470 par le Dr. Thomas Walters à la conférence ASCRS 2019 Recrutement des patients désormais de 90% Potentiel du NCX 470 pour la [...]
Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s
06/05/2019
Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented [...]
Addex to Present During the Swiss Biotech Day
06/05/2019
Geneva, Switzerland, May 6, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present the company at [...]
Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
05/05/2019
Trial Did Not Meet Statistical Significance for Primary Efficacy Analysis Patients on All Doses of Reldesemtiv Declined Less Than Patients on Placebo for SVC and ALSFRS-R, With Clinically Meaningful Differences Emerging [...]
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
05/05/2019
Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) New interim data from [...]
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting
05/05/2019
Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson’s Disease T reatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) [...]
Emerald Health Therapeutics annonce les résultats financiers du quatrième trimestre et de l’exercice 2018; faits saillants entourant la croissance des ventes au T1 2019
04/05/2019
Les ventes d’Emerald au T4 2018 et au T1 2019 ont fortement progressé par rapport à la même période l’an dernier et par rapport au trimestre précédent; la coentreprise Pure Sunfarms devrait enregistrer au premier [...]
RavenQuest Awarded its First Cannabis Sales License from Health Canada
03/05/2019
VANCOUVER, British Columbia, May 03, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “ Company ” or “ RavenQuest ”) a federally-licensed producer of cannabis, is pleased to [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/05/2019
BURLINGTON, Mass., May 03, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of an aggregate of 7,600 stock options and 1,250 [...]

Pages